Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Varsha Gandhi, PhD, on Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Sep
18
Today In Oncology
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
Independent Validation Supports Prognostic Value of Computational TILs in Triple-Negative Breast Cancer
NCCN Releases New Guideline for Patients and Caregivers: Older Adults With Cancer
First-Line Amivantamab/Chemotherapy in EGFR Exon 20 Insertion–Positive Advanced NSCLC
Alcohol-Attributable Cancer Deaths More Than Double in the United States
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo